A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

U Lin, Nancy; P Winer, Eric; Wheatley, Duncan; A Carey, Lisa; Houston, Stephen; Mendelson, David; Munster, Pamela; Frakes, Laurie; Kelly, Steve; A Garcia, Agustin; Cleator, Susan; Uttenreuther-Fischer, Martina; Jones, Hilary; Wind, Sven; Vinisko, Richard; Hickish, Tamas

doi:10.1007/s10549-012-2003-y

Public

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

Shared by NobleBlocks on Jun 1, 2012 • 12:00 AM UTC

Authors:

Nancy U Lin

Eric P Winer

Duncan Wheatley

Abstract

Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients progressing aft...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!